



Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: A randomized controlled trial

Janice K. Kiecolt-Glaser^{a,b,*}, Martha A. Belury^c, Rebecca Andridge^d, William B. Malarkey^{a,b,e}, Beom Seuk Hwang^{a,d}, Ronald Glaser^{a,f}

^a Institute for Behavioral Medicine Research, Ohio State University College of Medicine, OH, USA

^b Department of Psychiatry, Ohio State University College of Medicine, OH, USA

^c Department of Human Nutrition, Ohio State University, OH, USA

^d Division of Biostatistics, College of Public Health, Ohio State University, OH, USA

^e Department of Internal Medicine, Ohio State University College of Medicine, OH, USA

^f Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University College of Medicine, OH, USA

ARTICLE INFO

Article history:

Received 26 March 2012

Received in revised form 9 May 2012

Accepted 18 May 2012

Available online 26 May 2012

Keywords:

Fish oil

Omega-3

Omega-6

Interleukin-6

Tumor necrosis factor alpha

Psychoneuroimmunology

Integrative medicine

Nutritional neuroscience

ABSTRACT

Observational studies have linked lower levels of omega-3 (*n*-3) polyunsaturated fatty acids (PUFAs) with inflammation and depression. This study was designed to determine whether *n*-3 supplementation would decrease serum cytokine production and depressive symptoms in 138 healthy middle-aged and older adults (average age = 51.04, SD = 7.76) who were sedentary and overweight (average BMI = 30.59, SD = 4.50). This three-arm randomized, placebo-controlled, double-blind 4-month trial compared responses to (1) 2.5 g/d *n*-3 PUFAs, or (2) 1.25 g/d *n*-3 PUFAs, or (3) placebo capsules that mirrored the proportions of fatty acids in the typical American diet. Serum interleukin-6 decreased by 10% and 12% in our low and high dose *n*-3 groups, respectively, compared to a 36% increase in the placebo group. Similarly, low and high dose *n*-3 groups showed modest 0.2% and –2.3% changes in serum tumor necrosis factor alpha, compared to a 12% increase in the control group. Depressive symptoms were quite low at baseline and did not change significantly in response to supplementation. Our data suggest that *n*-3 PUFAs can reduce inflammation in overweight, sedentary middle-aged and older adults, and thus could have broad health benefits. These data provide a window into the ways in which the *n*-3 PUFAs may impact disease initiation, progression, and resolution.

ClinicalTrials.gov identifier: NCT00385723.

© 2012 Elsevier Inc. All rights reserved.

1. Introduction

1.1. Inflammation, mental and physical health, and omega-3

Inflammation is a robust and reliable predictor of all-cause mortality in older adults (Krabbe et al., 2004). Proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor- α (TNF- α) play a role in coronary heart disease (CHD), depression, type II diabetes, arthritis, osteoporosis, Alzheimer's disease, periodontal disease, and frailty and functional decline (Ferrucci et al., 2006; Krabbe et al., 2004). Fish, the prime source for the long-chain omega-3 (*n*-3) polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has generated

considerable interest as a potential anti-inflammatory food (Lee et al., 2009; Wall et al., 2010).

The positive effects of fish and fish oil consumption have been demonstrated across such diverse conditions as depression, CHD, rheumatoid arthritis, and macular degeneration (Goldberg and Katz, 2007; Hallahan and Garland, 2005; Hibbeln, 1998; Johnson and Schaefer, 2006; Wall et al., 2010). Although the health benefits of fish oil may arise through a number of different mechanisms, reduced inflammation appears to be one common pathway (Shelton and Miller, 2010).

A number of epidemiological and observational studies have demonstrated that lower *n*-3 PUFA levels are associated with higher serum IL-6, TNF- α , and CRP (Farzaneh-Far et al., 2009; Ferrucci et al., 2006; Kalogeropoulos et al., 2010; Kiecolt-Glaser et al., 2007). In contrast, comparisons of supplemented and placebo groups in *n*-3 PUFA randomized controlled trials (RCTs), the gold standard for demonstrating causality, have not produced reliable serum cytokine differences (Calder et al., 2009; Fritsche, 2006; Kiecolt-Glaser et al., 2011; Sijben and Calder, 2007). Problematic methodological issues

* Corresponding author. Address: Institute for Behavioral Medicine Research, Ohio State University College of Medicine, 460 Medical Center Drive, Columbus, OH 43210, USA. Tel.: +1 614 293 3499; fax: +1 614 366 3627.

E-mail address: Janice.Kiecolt-Glaser@osumc.edu (J.K. Kiecolt-Glaser).

that muddy interpretation have included severely underpowered small treatment groups (e.g., 8–10 per group), low *n*-3 PUFA supplementation doses, insensitive cytokine assays, use of young and healthy subjects and/or highly-trained athletes, and very low levels of baseline inflammation. For example, serum cytokines did not differ significantly among 58 monks who received 0, 1.06, 2.13 or 3.19 g/d of *n*-3 PUFAs for a year (Blok et al., 1997); however, basal cytokine data did not differ between vegetarians and non-vegetarians even before supplementation, suggesting that the monks' extremely healthy lifestyle limited the ability to see meaningful downward change.

The strongest RCT support for the *n*-3 PUFA's anti-inflammatory properties has come from studies with older, hypertriglyceridemic or diabetic individuals with elevated inflammatory markers (Fritsche, 2006; Sijben and Calder, 2007; Wu, 2004; Yusof et al., 2008). Consequently, it has been suggested that cytokine production in healthy people is relatively insensitive to long-chain *n*-3 PUFAs (Sijben and Calder, 2007; Wu, 2004).

1.2. The present study

Although the health benefits of the *n*-3 PUFAs are well established, particularly their cardioprotective and antidepressant impacts, clear evidence that small dietary changes modulate inflammation in healthy people would provide a window into the ways in which dietary *n*-3 PUFAs alter disease initiation, progression, and resolution (Fritsche, 2006). Accordingly, this study assessed the impact of long-chain *n*-3 PUFA supplementation on inflammation in healthy sedentary overweight middle-aged and older adults. We hypothesized that *n*-3 PUFA supplementation would decrease our primary outcomes, proinflammatory cytokine production and depressive symptoms, in contrast to placebo.

2. Methods

2.1. Participants

The 138 participants, 45 men and 93 women, ranged in age from 40 to 85 (Table 1). Campus and community print and web-based announcements were used for recruitment. The institutional review board approved this study, and each participant provided informed consent.

The online screening form assessed health history, medications, and health behaviors. Exclusions included psychoactive drugs or mood altering medications, lipid-altering drugs, beta blockers, steroids, regular use of non-steroidal anti-inflammatory drugs other than an aspirin a day, ACE-inhibitors, prostaglandin inhibitors, heparin, warfarin, and alcohol/drug abuse (Buckley et al., 2004; Ferrucci et al., 2006). We also excluded pregnant or nursing women,

vegetarians, diabetics, people who routinely took fish oil or flaxseed supplements or ate more than two portions of oily fish per week, smokers, and individuals with recurrent digestive problems, convulsive disorders, and autoimmune and/or inflammatory diseases. Individuals who typically engaged in 2 or more hours of vigorous physical activity per week, as well as individuals with a body mass index (BMI) less than 22.5 or greater than 40 were excluded (Fernandez-Real et al., 2003).

In addition, we used participants' ability to follow the regimen as a criterion for study entry. Participants received a 7-day supply of placebo capsules (single blind) at the subsequent in-person screening session, and those who had taken less than 80% of the capsules a week later were dropped before randomization. We also verified height and weight at the screening visit.

2.2. Design and study components

Data collection for this double-blind placebo-controlled four month randomized clinical trial (RCT) began in September, 2006 and ended in February, 2011. Fasting blood samples were collected between 7:00 and 9:00 AM to control for diurnal variation.

2.2.1. Supplement and placebo

This three-arm parallel group RCT compared responses to (A) 2.496 g/d *n*-3, (B) 1.25 g/d *n*-3, and placebo, or (C) placebo. All participants took 6 pills (3 g oil) per day. For the two omega-3 groups, each 500 mg gel capsule contained 347.5 mg eicosapentaenoic acid (EPA) and 58 mg docosahexaenoic acid (DHA). Thus, for the high dose group the full daily supplement would equal 2085 mg/d of EPA and 348 mg/d of DHA. We chose the 7:1 EPA/DHA balance because of evidence that EPA has relatively stronger anti-inflammatory and antidepressant effects than DHA (Lin et al., 2010; Sijben and Calder, 2007). The placebo was a mixture of palm, olive, soy, canola, and coco butter oils that approximated the saturated:monounsaturated:polyunsaturated (SMP) ratio consumed by US adults, 37:42: 21 (USDA Continuing Survey of Food Intake by Individuals, 1994–1996). OmegaBrite (Waltham, MA) supplied both the *n*-3 and the matching placebo; all pills were coated with a fuchsia coloring. OmegaBrite added a mild fish flavor to the placebo to help disguise any differences between the *n*-3 PUFA pills and the placebo, and we told participants about the fish flavoring to promote blindness (Stoll et al., 2001). Table 2 shows the results of our independent analysis of the fatty acid profile of the *n*-3 and placebo pills.

2.2.2. Randomization and masking

Before a participant left the baseline session, s/he was randomly assigned to one of three treatment groups using a permuted block randomization sequence prepared and maintained by the data manager who had no involvement in data collection or biological

Table 1
Baseline characteristics.

	Placebo (n = 46)	1.25 g/d (n = 46)	2.5 g/d (n = 46)
Age (years)	51.1 (8.6)	51.1 (8.0)	51.0 (6.7)
Female	36 (78%)	28 (61%)	29 (63%)
Race			
White	33 (72%)	39 (85%)	37 (80%)
Black	9 (20%)	5 (11%)	8 (17%)
Asian	2 (4%)	1 (2%)	1 (2%)
Other	2 (4%)	1 (2%)	0 (0%)
Sagittal abdominal diameter (cm)	22.8 (3.2)	23.9 (3.4)	22.9 (2.9)
CES-D			
Median (IQR)	5 (3–9)	5 (2–11)	6 (2–10)
Range	0–50	0–43	0–32

Data are mean (SD) or n (%) except where noted. There were no significant differences on any of the participant characteristics ($p > 0.1$ for all tests).

Table 2

Fatty acid composition of the dietary supplements as determined by independent analysis.

		Placebo % Fatty acid	Supplement % Fatty acid
C14:0	Myristic acid	3.1	0.0
C16:0	Palmitic acid	16.4	0.1
C18:0	Stearic acid	3.2	0.5
C18:1n9	Oleic acid	48.7	0.7
C18:1n7	Vaccenic acid	1.6	0.3
C18:2n6	Linoleic acid	21.5	0.2
C18:3n3	Alpha linolenic acid	3.3	0.2
C18:4n3	Stearidonic acid	0.1	6.4
C20:4n6	Arachidonic acid	0.1	3.2
C20:4n3	Eicosatetraenoic acid	0.0	1.0
C20:5n3	Eicosapentaenoic acid	1.0	76.8
C22:6n3	Docosahexaenoic acid	0.1	8.5

laboratory analyses; she was the only person who had access to the randomization list. The active and placebo study medications were packaged according to the randomization sequence, so that a participant was randomized to the next available individual supply of study medication. At each subsequent study visit, participants returned unused pills and received the next month's supply. Blinding was assessed at the final visit.

2.3. Health-related behaviors

Participants' height and weight were assessed at the screening visit, and participants were weighed during each subsequent visit. At each study visit, participants were evaluated for changes in fatty acid composition of plasma and PBMCs, mood, and proinflammatory cytokines.

Adipose tissue in the abdomen may secrete up to three times as much IL-6 as other subcutaneous fat tissues (Browning, 2003). Sagittal abdominal diameter measurements provided data on abdominal fat. Sagittal abdominal diameter was assessed by measuring the distance from the small of the back to the upper abdomen midway between the top of the pelvis and the base of the ribs when the participant was lying on their back. Validation studies using computerized axial tomography and dual-energy X-ray absorptiometry have demonstrated sagittal abdominal diameter's utility as a noninvasive central adiposity measure (Clasey et al., 1999).

The Women's Health Initiative Food Frequency Questionnaire (FFQ), completed during the screening session and repeated at the end of the trial, provided data on the type, frequency, and quantity of foods and beverages consumed in the past 90 days (Patterson et al., 1999). The precision is similar to other FFQs, and means are within 10% of dietary records or recalls. Software calculations estimated dietary intake of energy, macro- and micro-nutrients, as well as intake of key food groups using the Nutrition Data Systems for Research. Participants were asked not to change their diet during the trial were told not to take any fish oil or other *n-3* supplements other than those provided by the study.

The Pittsburgh Sleep Quality Index (PSQI) assessed sleep quality and disturbances over a one-month interval; it has good diagnostic sensitivity and specificity (Buysse et al., 1989). We used the full scale at baseline and at 4 months. In addition, we also assessed sleep efficiency for the prior night (Vgontzas et al., 1999).

The Community Healthy Activities Model Program for Seniors Questionnaire (CHAMPS) assessed the weekly frequency and duration of various physical activities at baseline and 4 months. An excellent instrument for middle-aged and older populations, it has a strong history of validation and testing, and it is sensitive to relatively small changes in physical activity (Harada et al., 2001; Resnicow et al., 2003; Stewart et al., 2001a,b).

The modified version of the Health Review, administered monthly, provided data on infectious illness symptoms as well as possible supplementation side effects (Jenkins et al., 1980; Orts et al., 1995). Developed to provide a simple reliable and valid method for periodic assessment of infectious illness, the symptoms assessed also include the primary gastrointestinal side effects described for *n-3* PUFA supplementation.

2.4. Depressive symptoms

The Center for Epidemiological Studies Depression Scale (CES-D), administered at all visits, has been used extensively to measure depressive symptomatology (Basco et al., 1997; Radloff, 1977). Studies have shown acceptable test–retest reliability and excellent construct validity (Basco et al., 1997).

2.5. Fatty acid analyses

Lipids were extracted from plasma and PBMCs using chloroform: methanol (2:1, v/v) with 0.2 vol. 0.88% KCl (Bligh and Dyer, 1959). Fatty acid methyl esters of the fractions were prepared by incubating the fractions with tetramethylguanidine at 100 °C (Shantha et al., 1993) and analyzed by gas chromatography (Shimadzu, Columbia, MD) using a 30-m Omegawax 320 (Supelco-Sigma) capillary column. The helium flow rate was 30 ml/min and oven temperature ramped beginning at 175 °C and held for 4 min then increased to 220 °C at a rate of 3 °C/min as previously described (Belury and Kempa-Steczko, 1997). Retention times were compared to authentic standards for fatty acid methyl esters (Supelco-Sigma, St. Louis, MO and Matreya, Inc., Pleasant Gap, PA).

2.6. Immunological assays

Serum levels of IL-6 and TNF- α were multiplexed and measured using an electrochemiluminescence method with Meso Scale Discovery kits, and read using the Meso Scale Discovery Sector Imager 2400. Each subject's stored samples were assayed for all the cytokine markers in one run, thus using the same controls for all time points for each person. Sensitivity for these serum cytokines was 0.3 pg/ml. The intra-assay coefficient of variation for IL-6 was 2.8%, and the inter-assay coefficient of variation was 12.5%; corresponding values for TNF- α were 4.3% and 12.1%.

2.7. Sample size

Sample size was based on detection of conservative effect sizes for the lower dose versus placebo comparisons for the primary outcome of cytokine levels. The literature suggested that the higher dose would have a greater effect, thus we expected the higher dose versus placebo contrast to have more power than low versus placebo. All power analyses were based on contrasts within mixed effect linear models with two-sided $\alpha = 0.05$ and assumed a 10% attrition rate. Our conservative estimated effect size was a decrease in IL-6 of 0.45 pg/mL in the low dose group, extrapolated from results from Ferrucci et al. (2006). Pilot data from our lab provided an estimate of standard deviation of 0.88 pg/mL, thus to achieve 85% power a sample size of 46 in each group was required.

2.8. Statistical methods

Mixed models were used to test the effects of supplementation on proinflammatory cytokine levels and depressive symptoms (Diggle et al., 2002). This type of model treats the responses from each subject as repeated measures, accounting for the within-subject correlation. Compound symmetry variance–covariance structure was used to account for the correlation within subjects. In

models for serum cytokines random effects for the assay plate and assay lot were also included. To test for treatment group differences, models included the effects of visit, treatment group, and their interaction. Outcome variables were natural log transformed when residual analyses suggested violation of the normality assumption. P-values from between-group comparisons were Bonferroni-adjusted within outcome model since three pairwise group comparisons were performed for each model.

Differences in the proportions experiencing nonserious adverse events between treatment groups were evaluated using Fisher's exact test. James' blinding indices were calculated using participant and experimenter guesses about treatment assignment at the final study visit (James et al., 1996). Alpha was set to 0.05, and two-sided tests were conducted. All analyses were carried out in SAS version 9.1 (SAS Institute, Cary, NC).

3. Results

3.1. Study population, diet, and health behaviors

Randomized groups were equivalent on key dimensions (Table 1). Randomization produced groups that did not differ on age, baseline FFQ dietary variables, depression, and sleep quality, $p > 0.2$ for all tests. Using BMI cut points of 25 and 30 kg/m², 125 (91%) were overweight, and 65 (47%) were obese, respectively. There were small differences between groups on weight at baseline ($p = 0.002$), with the placebo group having the lowest average weight, however there were not significant differences in either sagittal abdominal diameter or BMI ($p > 0.05$ for both).

Analyses of FFQ data at the last visit revealed no differences among the groups in reported changes in intake of calories, fiber, total fat, protein, saturated fat, monounsaturated fat, polyunsaturated fat, omega-3 fatty acids, or linoleic acid during the study period, $P > .11$ for all tests. Similarly, sleep and exercise did not show differential group changes, $P > .26$ for both. Both the lower and higher *n-3* groups had modest but statistically significant increases in weight across the trial (average pounds gained: 2.1 lbs and 2.5 lbs in the two groups, respectively), compared to no change in the placebo group (average pounds gained: 0.39 lbs). However, the increased weight would have theoretically fueled inflammation in this overweight sample which was not observed.

Few participants reported taking any medication during the study, and the numbers did not differ among groups. The most common medications were multivitamins ($n = 42$), NSAIDs ($n = 29$; 15 aspirin, 8 ibuprofen, 5 naproxen, 1 meloxicam), antihistamines ($n = 13$), estrogen with or without progesterone ($n = 10$), and levothyroxine ($n = 10$).

3.2. Protocol adherence and blinding

Of the 138 randomized subjects, 133 (96%) completed all five visits (Fig. 1). Protocol adherence was measured by the number of pills returned at each study visit. There was no difference in adherence between the active and placebo groups, with 3.3%, 2.0%, and 2.6% percent of pills returned in the placebo, 1.25 g/d, and 2.5 g/d groups, respectively ($p = 0.31$). The mean number of pills taken per day was 5.8 in the placebo and 2.5 g/d groups, and 5.9 in the 1.25 g/d group.

The James' blinding index for participants at the end of the study was 0.60 (95% CI: 0.53–0.68, $n = 131$) (James et al., 1996). For the two experimenters the James' blinding indices were 0.83 (95% CI: 0.77–0.88, $n = 130$) and 0.81 (95% CI: 0.75–0.87, $n = 116$), respectively. Blinding is considered adequate if the index is greater than 0.5.

3.3. Safety and tolerability

Nonserious adverse events reported by at least one subject are summarized in Table 4. There were no significant group differences on any dimension.

3.4. Changes in fatty acids

Baseline levels of plasma fatty acids as well as changes over time for the three groups are summarized in Table 3. As expected, randomization produced groups that did not differ on EPA ($p = 0.73$), DHA ($p = 0.38$), or total *n-3* ($p = 0.41$) at baseline. By the end of the study period plasma levels of EPA were approximately 3.5-fold higher in the 1.25 g/d *n-3* group and 6-fold higher in the 2.5 g/d *n-3* group ($P < 0.0001$ for both), and plasma DHA levels were approximately 1.4-fold higher in the 1.25 g/d *n-3* group and 1.5-fold higher in the 2.5 g/d *n-3* group ($P < 0.0001$ for both). The *n-6:n-3* ratio was significantly decreased after supplementation for both low and high dose groups ($P < 0.0001$ for both).

3.5. Primary Outcomes

Results for inflammatory outcomes and depression symptoms are summarized in Table 5. After adjusting for gender and sagittal abdominal diameter, there were significant supplementation effects on cytokines as evidenced by significant group by visit interactions for both TNF- α ($p = 0.0002$) and IL-6 ($p = 0.0003$). The estimated mean change in log-TNF- α from visit 1 to visit 5 was 0.11 units for the placebo group, corresponding to a 12% increase in the geometric mean of TNF- α . In comparison, the estimated mean change in log-TNF- α was 0.0002 units for the 1.25 g/d and -0.024 for the 2.5 g/d group, corresponding to changes of 0.2% and -2.3% , respectively. After Bonferroni-adjustment, these group differences were significant for the comparison of placebo to 1.25 g/d ($p = 0.03$) and placebo to 2.5 g/d ($p = 0.004$); no significant difference was noted between the two supplementation doses ($p = 1.0$).

A similar pattern was observed for IL-6. The estimated mean change in log-IL-6 from visit 1 to visit 5 was 0.31 units for the placebo group (36% increase), -0.106 for the 1.25 g/d group (10% decrease), and -0.123 for the 2.5 g/d group (12% decrease). Significant differences were observed between placebo and 1.25 g/d ($p = 0.0003$) and placebo and 2.5 g/d ($p = 0.0002$), but not between the two doses of fish oil ($p = 1.0$). To ensure that results were not driven by a small number of highly influential data points, residual plots were examined and one subject in the placebo group who appeared to be an outlier was removed and analyses were rerun. Resulting conclusions were the same and are not shown.

There did not appear to be group effects on depression ($p = 0.86$), adjusting for gender. There was a trend toward larger decreases in depression from visit 1 to visit 5 for the two fish oil groups than the placebo, but no differences were statistically significant.

4. Discussion

4.1. Intervention-related reductions in inflammation

Omega-3 supplementation significantly altered production of serum cytokines. IL-6 decreased by 10% and 12% in our low and high dose *n-3* groups, respectively, compared to a 36% increase in the placebo group. Similarly, low and high dose *n-3* groups showed modest 0.2% and -2.3% changes in TNF- α , compared to a 12% increase in the control group. This is the first well-powered trial to




Fig. 1. Screening, randomization, and participant flow by group.

show significant changes in serum cytokines in healthy middle-aged and older adults.

4.2. Randomized PUFA trials

The largely negative serum cytokine data from prior *n*-3 PUFA trials have led to the suggestion that cytokine production is relatively insensitive to the *n*-3 PUFAs among healthy individuals, i.e., people who do not have chronic inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, chronic obstructive pulmonary disease, or diabetes (Sijben and Calder, 2007; Wu, 2004). However, there are several notable differences between our study and prior RCTs. We carefully assessed variables known to influence inflammation including smoking, medication use, physical activity, and abdominal adiposity. We had minimal

attrition; only 5 of our 138 subjects failed to complete the full trial. Our rigorous exclusion criteria produced a group of overweight sedentary adults who were more likely to have an inflammatory profile and who were otherwise healthy aside from their weight. In addition, our supplement's 7:1 EPA:DHA ratio may be particularly beneficial based on evidence for EPA's anti-inflammatory properties (Ariel and Serhan, 2007; Sijben and Calder, 2007).

Dietary intakes of both the *n*-3 and omega-6 (*n*-6) PUFAs influence inflammation. Arachidonic acid (AA) is an *n*-6 polyunsaturated fatty acid derived from linoleic acid. The eicosanoids produced from enzymatic hydroxylation of AA increase proinflammatory cytokine production (Hibbeln et al., 2006). In contrast, the eicosanoids derived from *n*-3 PUFAs curb the production of AA-derived eicosanoids (Blasbalg et al., 2011; Pischon et al., 2003). Thus, both higher plasma levels of *n*-3 PUFAs

Table 3
Plasma fatty acids.^a

	Baseline (week 0)	Change visits 0–5	<i>P</i> for change ^b	<i>P</i> for comparison of changes ^c
EPA				
Placebo	0.46 ± 0.10	0.17 ± 0.13	0.19	<.0001
1.25 g/d <i>n</i> -3	0.53 ± 0.10	1.4 ± 0.13	<.0001	
2.5 g/d <i>n</i> -3	0.56 ± 0.10	2.9 ± 0.13	<.0001	
DHA				
Placebo	1.5 ± 0.09	0.07 ± 0.08	0.40	<.0001
1.25 g/d <i>n</i> -3	1.4 ± 0.09	0.60 ± 0.08	<.0001	
2.5 g/d <i>n</i> -3	1.6 ± 0.09	0.73 ± 0.08	<.0001	
Total <i>n</i>-3				
Placebo	3.7 ± 0.18	0.28 ± 0.24	0.25	<.0001
1.25 g/d <i>n</i> -3	4.0 ± 0.18	2.1 ± 0.24	<.0001	
2.5 g/d <i>n</i> -3	4.0 ± 0.18	4.3 ± 0.24	<.0001	
Total <i>n</i>-6				
Placebo	41 ± 0.82	−0.90 ± 0.86	0.30	0.01
1.25 g/d <i>n</i> -3	39 ± 0.82	0.41 ± 0.85	0.63	
2.5 g/d <i>n</i> -3	42 ± 0.82	−3.2 ± 0.86	0.0004	
<i>n</i>-6:<i>n</i>-3 ratio				
Placebo	11 ± 0.35	−0.81 ± 0.44	0.07	<.0001
1.25 g/d <i>n</i> -3	10 ± 0.35	−3.4 ± 0.44	<.0001	
2.5 g/d <i>n</i> -3	11 ± 0.35	−6.1 ± 0.44	<.0001	

^a All values are means ± SEMs from mixed effects models. Tests are for orthogonal contrasts in the models.

^b Within-group *t*-tests with degrees of freedom ranging from 132 to 136.

^c Between-group *F*-tests (visit by group interaction term) with degrees of freedom ranging from (2133) to (2136).

Table 4
Nonserious adverse events reported by at least one study subject during trial.

	Placebo (<i>n</i> = 46)	1.25 g/d <i>n</i> -3 (<i>n</i> = 46)	2.5 g/d <i>n</i> -3 (<i>n</i> = 46)	<i>P</i> -value
Ear ache	6 (13%)	4 (9%)	2(4%)	0.39
Sore throat	3(7%)	10 (22%)	8 (17%)	0.10
Swollen glands	1 (2%)	0 (0%)	1 (2%)	1.00
Stuffy nose	18 (39%)	20 (43%)	23 (50%)	0.60
Wheeze	3 (7%)	1 (2%)	2 (4%)	0.87
Dry cough	10 (22%)	10 (22%)	6 (13%)	0.50
Wet cough	8 (17%)	6 (13%)	6 (13%)	0.87
Nausea	7 (15%)	6 (7%)	8 (17%)	0.28
Stomach pain	12 (26%)	13 (28%)	14 (30%)	0.97
Diarrhea	10 (22%)	7 (15%)	12 (26%)	0.48
Other symptoms	25 (54%)	25 (54%)	23 (50%)	0.93

Data are *n* (%).

Table 5
Group effects^a on primary outcomes (natural log-transformed).

	Baseline (visit 1)	Change, visit 1 to 5	Difference in change versus placebo	95% CI	<i>P</i> -value ^b
Log (TNF-α)					
Placebo	0.66 (0.25)	0.11 (0.030)			
1.25 g/d <i>n</i> -3	0.74 (0.25)	0.002 (0.028)	−0.11 (0.04)	−0.028 to −0.19	0.03
2.5 g/d <i>n</i> -3	0.71 (0.25)	−0.024 (0.029)	−0.13 (0.04)	−0.052 to −0.22	0.004
Log (IL-6)					
Placebo	0.91 (0.60)	0.31 (0.077)			
1.25 g/d <i>n</i> -3	1.02 (0.60)	−0.106 (0.070)	−0.41 (0.10)	−0.21 to −0.62	0.0003
2.5 g/d <i>n</i> -3	0.85 (0.60)	−0.123 (0.074)	−0.43 (0.11)	−0.22 to −0.64	0.0002
CES-D, log					
Placebo	1.5 (0.17)	−0.056 (0.15)			
1.25 g/d <i>n</i> -3	1.5 (0.17)	−0.29 (0.15)	−0.23 (0.21)	−0.64 to 0.18	0.80
2.5 g/d <i>n</i> -3	1.6 (0.17)	−0.26 (0.15)	−0.20 (0.21)	−0.61 to 0.21	1.00

^a Least squares means (SE) adjusted for gender. Cytokine models additionally adjusted for sagittal abdominal diameter.

^b Comparison to placebo, Bonferroni-adjusted within outcome to account for multiple testing. Tests are *t*-tests with degrees of freedom ranging from 451 to 530. There were no significant differences between supplement doses. Excluded (*n* = 1868).

as well as lower plasma *n*-6:*n*-3 ratios should restrain proinflammatory cytokine production (Ferrucci et al., 2006). In this context it is noteworthy that our participants' average *n*-6:*n*-3 ratio at baseline was 10.82 (SD = 2.48, range = 3.3–18.8), considerably

lower than the 15:1 to 17:1 ratios reported for the contemporary North American diet (Hibbeln et al., 1997; Simopoulos, 2002). Accordingly, our data probably underestimate the potential impact of the *n*-3 PUFAs.

The absolute magnitude of the change in both IL-6 and TNF- α levels in the two treatment groups was smaller than the alterations in the placebo group. The *n*-3 PUFA's anti-inflammatory benefits may be both prophylactic (preventing an increase in inflammation) as well as therapeutic (decreasing elevated inflammatory cytokines), an important point for potential clinical utility.

Depressive symptoms were quite low at baseline and did not change significantly in response to supplementation; on entry into the trial, only 16 of our participants had a CES-D score of 16 or greater, the standard clinical cutoff used to define case status (Weissman et al., 1977). In a recent meta-analysis of randomized controlled trials, the authors concluded that *n*-3 PUFA supplementation benefited clinically depressed individuals, but not those with less severe depressed mood (Appleton et al., 2010).

In prior work from our laboratory, 68 medical students received either 2.5 g/d *n*-3 or a placebo for 12 weeks (Kiecolt-Glaser et al., 2011). Compared to controls, those students who received *n*-3 showed a 14% decrease in lipopolysaccharide (LPS) stimulated IL-6 production. Planned secondary analyses that used the plasma *n*-6:*n*-3 ratio in place of treatment group showed that decreasing *n*-6:*n*-3 ratios led to reductions in stimulated IL-6 and TNF- α production, as well as marginal differences in serum TNF- α . The absence of significant serum inflammatory changes was likely related to the very low baseline levels of serum cytokines in the healthy, young, and relatively thin population.

The majority of *n*-3 PUFA trials have used stimulated (*ex vivo*) production assays to assess changes in inflammation, rather than serum (*in vivo*) assays, and results of these trials have been mixed (Calder et al., 2009; Fritsche, 2006; Sijben and Calder, 2007). TNF- α and IL-6 are produced by a variety of types of cells, and thus serum cytokine levels may better reflect the overall inflammatory profile than stimulated production (Pischon et al., 2003). The absence of both normal values and clinical correlates for *ex vivo* assays limits inferences about *n*-3 PUFA's clinical therapeutic potential. Indeed, the health and aging literatures have focused on serum proinflammatory cytokine levels (Farzaneh-Far et al., 2009; Penninx et al., 2003; Taaffe et al., 2000). Thus, our finding that omega-3 supplementation can substantially change serum cytokines is important.

In accord with our findings, a recent study showed that consumption of 1.8 g/d of EPA + DHA changed the expression of 1040 genes, including decreased expression of genes involved in inflammatory and atherogenic pathways as well as NF- κ B signaling (Bouwens et al., 2009). In contrast, consumption of the high-oleic sunflower oil control only changed the expression of 298 genes (Bouwens et al., 2009).

4.3. Dosage and risks

Neither our IL-6 nor our TNF- α data showed significant differences between our 1.25 and 2.5 g/d *n*-3 dose, although both clearly differed from the placebo. One review concluded that while the effects were inconsistent, it appeared that significant changes in cytokine production by lymphocytes only occurred with ≥ 2.0 g/d of EPA + DHA (Sijben and Calder, 2007). In addition, variables such as typical dietary intake influence responses (Yee et al., 2010), and our sample had a higher than expected average *n*-6:*n*-3 ratio at baseline, as described earlier. The FDA has concluded that intakes of up to 3 g/d of marine *n*-3 PUFAs are "Generally Recognized As Safe" (Kris-Etherton et al., 2002); our higher dose, 2.5 g/d, fell within that range and would appear to be a good choice for future studies.

Side effects were infrequent and did not differ between groups. These data are in accord with the low incidence reported in large *n*-3 PUFA studies (Leaf et al., 1994; Valagussa et al., 1999).

4.4. Health implications

Several large studies have linked higher *n*-3 PUFA levels with lower all-cause mortality (Lee et al., 2009; Pottala et al., 2010), including a large 3.5 year trial (Marchioli et al., 2002). The *n*-3 PUFA's anti-inflammatory properties provide one obvious pathway for these reductions in mortality. Inflammation is a robust and reliable predictor of all-cause mortality in older adults (Pedersen and Febbraio, 2008). Chronic inflammation has been linked to a spectrum of health problems including depression, cardiovascular disease, osteoporosis, cancer, and arthritis (Pedersen and Febbraio, 2008). In fact, more globally, chronic inflammation has been suggested as one key biological mechanism that may fuel declines in physical function leading to frailty, disability, and, ultimately, death. Our data suggest that *n*-3 PUFAs can reduce inflammation in overweight, sedentary middle-aged and older adults, and thus could have broad health benefits. Although the *n*-3 PUFAs cannot take the place of good health behaviors like exercise, individuals who are at risk because of established inflammatory diseases or conditions may profit from their use. These data provide a window into the ways in which the *n*-3 PUFAs may impact disease initiation, progression, and resolution.

Acknowledgements

The study was supported in part by NIH Grants AG029562, UL1RR025755, and CA16058. OmegaBrite (Waltham, MA) supplied the omega-3 supplement and placebo without charge and without restrictions; OmegaBrite did not influence the design, funding, implementation, interpretation, or publication of the data.

References

- Appleton, K.M., Rogers, P.J., Ness, A.R., 2010. Updated systematic review and meta-analysis of the effects of *n*-3 long-chain polyunsaturated fatty acids on depressed mood. *Am. J. Clin. Nutr.* 91, 757–770.
- Ariel, A., Serhan, C.N., 2007. Resolvins and protectins in the termination program of acute inflammation. *Trends Immunol.* 28, 176–183.
- Basco, M.R., Krebaum, S.R., Rush, A.J., 1997. Outcome measures of depression. In: Strupp, H.H., Horowitz, L.M., Lambert, M.J. (Eds.), *Measuring patient changes in mood, anxiety, and personality disorders*. American Psychological Association, Washington, DC, pp. 207–245.
- Belury, M.A., Kempa-Steczko, A., 1997. Conjugated linoleic acid modulates hepatic lipid composition in mice. *Lipids* 32, 199–204.
- Blasbalg, T.L., Hibbeln, J.R., Ramsden, C.E., Majchrzak, S.F., Rawlings, R.R., 2011. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. *Am. J. Clin. Nutr.* 93, 950–962.
- Bligh, W.J., Dyer, E.G., 1959. A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* 37, 911–917.
- Blok, W.L., Deslypere, J.P., Demacker, P.N., van der Ven-Jongekrijg, J., Hectors, M.P., van der Meer, J.W., Katan, M.B., 1997. Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. *Eur. J. Clin. Invest.* 27, 1003–1008.
- Bouwens, M., van de Rest, O., Dellschaft, N., Bromhaar, M.G., de Groot, L.C., Geleijnse, J.M., Muller, M., Afman, L.A., 2009. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. *Am. J. Clin. Nutr.* 90, 415–424.
- Browning, L.M., 2003. *n*-3 Polyunsaturated fatty acids, inflammation and obesity-related disease. *Proc. Nutr. Soc.* 62, 447–453.
- Buckley, M.S., Goff, A.D., Knapp, W.E., 2004. Fish oil interaction with warfarin. *Ann. Pharmacother.* 38, 50–52.
- Buyse, D.J., Reynolds, C.F., Monk, T.H., Berman, S.R., Kupfer, D.J., 1989. Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res.* 28, 193–213.
- Calder, P.C., Albers, R., Antoine, J.M., Blum, S., Bourdet-Sicard, R., Ferns, G.A., Folkerts, G., Friedmann, P.S., Frost, G.S., Guarner, F., Lovik, M., Macfarlane, S., Meyer, P.D., M'Rabet, L., Serafini, M., van Eden, W., van Loo, J., Vas Dias, W., Vidry, S., Winkhofer-Roob, B.M., Zhao, J., 2009. Inflammatory disease processes and interactions with nutrition. *Br. J. Nutr.* 101 (Suppl. 1), S1–45.
- Clasey, J.L., Bouchard, C., Teates, C.D., Riblett, J.E., Thorner, M.O., Hartman, M.L., Weltman, A., 1999. The use of anthropometric and dual-energy X-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women. *Obes. Res.* 7, 256–264.
- Diggle, P., Heagerty, P., Liang, K.Y., Zeger, S.L., 2002. *Analysis of longitudinal data*. Clarendon Press, USA, Oxford.

- Farzaneh-Far, R., Harris, W.S., Garg, S., Na, B., Whooley, M.A., 2009. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: the heart and soul study. *Atherosclerosis* 205, 538–543.
- Fernandez-Real, J.-M., Broch, M., Vendrell, J., Ricart, W., 2003. Insulin resistance, inflammation, and serum fatty acid composition. *Diabetes Care* 26, 1362–1368.
- Ferrucci, L., Cherubini, A., Bandinelli, S., Bartali, B., Corsi, A., Lauretani, F., Martin, A., Andres-Lacueva, C., Senin, U., Guralnik, J.M., 2006. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. *J. Clin. Endocrinol. Metab.* 91, 439–446.
- Fritsche, K., 2006. Fatty acids as modulators of the immune response. *Annu. Rev. Nutr.* 26, 45–73.
- Goldberg, R.J., Katz, J., 2007. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. *Pain* 129, 210–223.
- Hallahan, B., Garland, M.R., 2005. Essential fatty acids and mental health. *Br. J. Psychiatry* 186, 275–277.
- Harada, N.D., Chiu, V., Stewart, A.L., 2001. An evaluation of three self-report physical activity instruments for older adults. *Med. Sci. Sports Exerc.* 33, 962–970.
- Hibbeln, J.R., 1998. Fish consumption and major depression. *Lancet* 351, 1213.
- Hibbeln, J.R., Nieminen, L.R., Blasbalg, T.L., Riggs, J.A., Lands, W.E.M., 2006. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. *Am. J. Clin. Nutr.* 83, 1483S–1493S.
- Hibbeln, J.R., Umhau, J.C., George, D.T., Salem, N.J., 1997. Do plasma polyunsaturates predict hostility and depression? *World Rev. Nutr. Diet.* 82, 175–186.
- James, K.E., Bloch, D.A., Lee, K.K., Kraemer, H.C., Fuller, R.K., 1996. An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation – a VA cooperative study. *Stat. Med.* 15, 1421–1434.
- Jenkins, C.D., Krueger, B.E., Rose, R.M., Hurst, M.W., 1980. Use of a monthly health review to ascertain illness and injuries. *Am. J. Public Health* 70, 82–84.
- Johnson, E.J., Schaefer, E.J., 2006. Potential role of dietary n-3 fatty acids in the prevention of dementia and macular degeneration. *Am. J. Clin. Nutr.* 83S, 1494S–1498S.
- Kalogeropoulos, N., Panagiotakos, D.B., Pitsavos, C., Chrysoshoou, C., Rousinou, G., Toutouza, M., Stefanadis, C., 2010. Unsaturated fatty acids are inversely associated and n-6/n-3 ratios are positively related to inflammation and coagulation markers in plasma of apparently healthy adults. *Clin. Chim. Acta* 411, 584–591.
- Kiecolt-Glaser, J.K., Belury, M.A., Porter, K., Beversdorf, D., Lemeshow, S., Glaser, R., 2007. Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults. *Psychosom. Med.* 69, 217–224.
- Kiecolt-Glaser, J.K., Belury, M.A., Andridge, R., Malarkey, W.B., Glaser, R., 2011. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. *Brain. Behav. Immun.* 25, 1725–1734.
- Krabbe, K.S., Pedersen, M., Bruunsgaard, H., 2004. Inflammatory mediators in the elderly. *Exp. Gerontol.* 39, 687–699.
- Kris-Etherton, P.M., Harris, W.S., Appel, L.J., 2002. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation* 106, 2747–2757.
- Leaf, A., Jorgensen, M.B., Jacobs, A.K., Cote, G., Schoenfeld, D.A., Scheer, J., Weiner, B.H., Slack, J.D., Kellett, M.A., Raizner, A.E., 1994. Do fish oils prevent restenosis after coronary angioplasty? *Circulation* 90, 2248–2257.
- Lee, J.H., O'Keefe, J.H., Lavie, C.J., Harris, W.S., 2009. Omega-3 fatty acids: cardiovascular benefits, sources and sustainability. *Nat. Rev. Cardiol.* 6, 753–758.
- Lin, P.Y., Huang, S.Y., Su, K.P., 2010. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. *Biol. Psychiatry* 68, 140–147.
- Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M.G., Geraci, E., Levantesi, G., Maggioni, A.P., Mantini, L., Marfisi, R.M., Mastrogiuseppe, G., Mininni, N., Nicolosi, G.L., Santini, M., Schweiger, C., Tavazzi, L., Tognoni, G., Tucci, C., Valagussa, F., Investigators, G.I.-P., 2002. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction – Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation* 105, 1897–1903.
- Orts, K., Sheridan, J.F., Robinson-Whelen, S., Glaser, R., Malarkey, W.B., Kiecolt-Glaser, J.K., 1995. The reliability and validity of a structured interview for the assessment of infectious illness. *J. Behav. Med.* 18, 517–530.
- Patterson, R.E., Kristal, A.R., Carter, R.A., Fels-Tinker, L.F., Bolton, M.P., Argurs-Collins, T., 1999. Measurement characteristics of the Women's Health Initiative Food Frequency Questionnaire. *Ann. Epidemiol.* 9, 178–187.
- Pedersen, B.K., Febbraio, M.A., 2008. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. *Physiol. Rev.* 88, 1379–1406.
- Penninx, B.W.J.H., Kritchinsky, S.B., Yaffe, K., Newman, A.B., Sisonick, E.M., Rubin, S., Ferrucci, L., Harris, T., Pahor, M., 2003. Inflammatory markers and depressed mood in older persons: results from the health, aging, and body composition study. *Biol. Psychiatry* 54, 566–572.
- Pischon, T., Hankinson, S.E., Hotamisligil, G.S., Rifai, N., Willett, W.C., Rimm, E.B., 2003. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. *Circulation* 108, 155–160.
- Pottala, J.V., Garg, S., Cohen, B.E., Whooley, M.A., Harris, W.S., 2010. Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: the heart and soul study. *Circ. Cardiovasc. Qual. Outcomes* 3, 406–412.
- Radloff, L.S., 1977. The CES-D scale: a self-report depression scale for research in the general population. *Appl. Psychol. Meas.* 1, 385–401.
- Resnicow, K., McCarty, F., Blissett, D., Wang, T., Heitzler, C., Lee, R.E., 2003. Validity of a modified CHAMPS physical activity questionnaire among African-Americans. *Med. Sci. Sports Exerc.* 35, 1537–1545.
- Shantha, N.C., Decker, E.A., Hennig, B., 1993. Comparison of methylation methods for the quantitation of conjugated linoleic acid isomers. *J. AOAC Int.* 76, 644–649.
- Shelton, R.C., Miller, A.H., 2010. Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. *Prog. Neurobiol.* 91, 275–299.
- Sijben, J.W.C., Calder, P.C., 2007. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. *Proc. Nutr. Soc.* 66, 237–259.
- Simopoulos, A.P., 2002. Omega-3 fatty acids in inflammation and autoimmune diseases. *J. Am. Coll. Nutr.* 21, 495–505.
- Stewart, A.L., Mills, K.M., King, A.C., Haskell, W.L., Gillis, D., Ritter, P.L., 2001a. CHAMPS physical activity questionnaire for older adults: outcomes for interventions. *Med. Sci. Sports Exerc.* 33, 1126–1141.
- Stewart, A.L., Verboncoeur, C.J., McLellan, B.Y., Gillis, D.E., Rush, S., Mills, K., King, A.C., Ritter, P., Brown, B., Bortz, W.M., 2001b. Physical activity outcomes of CHAMPS II: a physical activity promotion program for older adults. *J. Gerontol. A Biol. Sci. Med. Sci.* 56A, m465–m470.
- Stoll, A.L., Damico, K.E., Daly, B.P., Severus, W.E., Marangell, L.B., 2001. Methodological considerations in clinical studies of omega 3 fatty acids in major depression and bipolar disorder. *World Rev. Nutr. Diet.* 88, 58–67.
- Taaffe, D.R., Harris, T.B., Ferrucci, L., Rowe, J., Seeman, T.E., 2000. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur Studies of Successful Aging. *J. Gerontol. A Biol. Sci. Med. Sci.* 55, M709–715.
- US Department of Agriculture, Agricultural Research Service. Intakes of 19 individual fatty acids: results from 1994–96, continuing survey of food intakes by individuals. Available from: <<http://www.barc.usda.gov/bhnr/foodsurvey/home.htm>>.
- Valagussa, F., Franzosi, M.G., Geraci, E., Mininni, N., Nicolosi, G.L., Santini, M., Tavazzi, L., Vecchio, C., Marchioli, R., Bomba, E., Chieffo, C., Maggioni, A.P., Schweiger, C., Tognoni, G., Barzi, F., Flamminio, A.V., Marfisi, R.M., Olivieri, M., Pera, C., Polidoro, A., Santoro, E., Zama, R., Pagliaro, L., Correale, E., Del Favero, A., Loi, U., Marubini, E., Campolo, L., Casari, A., Di Minno, G., Donati, M.B., Galli, M., Gattone, M., Garattini, S., Mancini, M., Marino, P., Santoro, G.M., Scardulla, C., Specchia, G., Cericola, A., Di Gregorio, D., Di Mascio, R., Levantesi, G., Mantini, L., Mastrogiuseppe, G., Tucci, C., Mocarelli, P., Baldinelli, R., Ceriotti, F., Colonna, A., Cortese, C., Fortunato, G., Franzini, C., Gonano, F., Graziani, M.S., Investigators, G.I.-P., 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. *Lancet* 354, 447–455.
- Vgontzas, A.N., Papanicolaou, D.A., Bixler, E.O., Loutsikas, A., Zachman, K., Kales, A., Prolo, P., Wong, M.L., Licinio, J., Gold, P.W., Hermida, R.C., Matorakos, G., Chrousos, G.P., 1999. Circadian interleukin-6 secretion and quantity and depth of sleep. *J. Clin. Endocrinol. Metab.* 84, 2603–2607.
- Wall, R., Ross, R.P., Fitzgerald, G.F., Stanton, C., 2010. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. *Nutr. Rev.* 68, 280–289.
- Weissman, M.M., Sholomskas, D., Pottenger, M., Prusoff, B.A., Locke, B.Z., 1977. Assessing depressive symptoms in five psychiatric populations: a validation study. *Am. J. Epidemiol.* 106, 203–214.
- Wu, D.Y., 2004. Modulation of immune and inflammatory responses by dietary lipids. *Curr. Opin. Lipidol.* 15, 43–47.
- Yee, L.D., Lester, J.L., Cole, R.M., Richardson, J.R., Hsu, J.C., Li, Y., Lehman, A., Belury, M.A., Clinton, S.K., 2010. Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition. *Am. J. Clin. Nutr.* 91, 1185–1194.
- Yusuf, H.M., Miles, E.A., Calder, P., 2008. Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men. *Prostaglandins Leukot. Essent. Fatty Acids* 78, 219–228.